|
|
Baxter International Inc (BAX) |
|
|
|
| |
Baxter International Inc 's Leverage Ratio
BAX's quarterly Leverage Ratio and Total Liabilities, Equity growth
In Spite of the repayements of liabilities of -4.82%, in II Quarter 2024 ,Leverage Ratio deteriorated to 2.42 is above the company's typical Leverage Ratio.
Within Medical Equipment & Supplies industry in the second quarter 2024, 77 other companies have achieved lower Leverage Ratio than Baxter International Inc in the II Quarter 2024. While Leverage Ratio total ranking has improved so far in the second quarter 2024 to 1505, from total ranking in the first quarter 2024 at 1832 .
Explain Leverage Ratio?
Who are BAX Customers?
What are BAX´s Total Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BAX Leverage Ratio |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Sep 30 2023)
III. Quarter |
(Jun 30 2023)
II. Quarter |
| Y / Y Equity Change |
36.89 % |
38.61 % |
43.65 % |
46.37 % |
-36.75 % |
| Y / Y Total Liabilities Change |
-16.34 % |
-12.48 % |
-11.49 % |
0.56 % |
-2.86 % |
| Leverage Ratio MRQ |
2.42 |
2.38 |
2.35 |
2.76 |
3.96 |
| BAX's Total
Ranking |
# 1505 |
# 1832 |
# 599 |
# 2435 |
# 2453 |
| Seq. Equity Change |
-6.4 % |
-2.75 % |
3.7 % |
45.02 % |
-5.22 % |
| Seq. Total Liabilities Change |
-4.82 % |
-1.3 % |
-11.89 % |
1.07 % |
-0.43 % |
| Leverage Ratio second quarter 2024 Company Ranking |
| Within: |
No. |
| Medical Equipment & Supplies Industry |
# 78 |
| Healthcare Sector |
# 304 |
| Overall Market |
# 1505 |
| Leverage Ratio Statistics |
| High |
Average |
Low |
| 4.02 |
1.77 |
0.8 |
| (Sep 30 2022) |
|
(Mar 31 2017) |
Cumulative Baxter International Inc 's Leverage Ratio
BAX's Leverage Ratio for the trailling 12 Months
BAX Leverage Ratio |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Sep 30 2023)
III. Quarter |
(Jun 30 2023)
II. Quarter |
| Y / Y Equity TTM Growth |
36.89 % |
38.61 % |
43.65 % |
46.37 % |
-36.75 % |
| Y / Y Total Liabilities TTM Growth |
-16.34 % |
-12.48 % |
-11.49 % |
0.56 % |
-2.86 % |
| Leverage Ratio TTM |
2.48 |
2.77 |
3.09 |
3.5 |
3.89 |
| Total
Ranking TTM |
# 1427
| # 139
| # 2107
| # 30
| # 33
|
| Seq. Equity TTM Growth |
-6.4 % |
-2.75 % |
3.7 % |
45.02 % |
-5.22 % |
| Seq. Total Liabilities TTM Growth |
-4.82 % |
-1.3 % |
-11.89 % |
1.07 % |
-0.43 % |
On the trailing twelve months basis Due to repayements of liabilities of -4.82% Baxter International Inc decreased Leverage Ratio in the 12 months ending in II Quarter 2024 to 2.48, above the Baxter International Inc 's average Leverage Ratio. Leverage Ratio is the average cumulative value over the last four quarters.
Among companies in the Medical Equipment & Supplies industry 77, during the past 12 months, other companies have achieved lower Leverage Ratio than Baxter International Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the II Quarter 2024, compared to the prior period, from 139 to 1427.
Explain Leverage Ratio?
Who are BAX Customers?
What are BAX´s Total Liabilities?
| TTM Leverage Ratio Company Ranking |
| Within: |
No. |
| Within the Medical Equipment & Supplies Industry |
# 78 |
| Healthcare Sector |
# 295 |
| Within the Market |
# 1427 |
| trailing twelve months Leverage Ratio Statistics |
| High |
Average |
Low |
| 3.88 |
1.66 |
0.84 | | (Jun 30 2023) |
|
(Jun 30 2017) |
| Companies with similar Leverage Ratio in the quarter ending Jun 30 2024, within Medical Equipment & Supplies Industry | Leverage Ratio | Jun 30 2024 MRQ Total Liabilities | Jun 30 2024 MRQ Equity | | 6.22 | $ 5.174 Millions | $ 0.832 Millions | | Establishment Labs Holdings Inc | 5.23 | $ 235.420 Millions | $ 45.019 Millions | | Owens and Minor inc | 4.78 | $ 4,116.674 Millions | $ 860.702 Millions | | Safe Pro Group Inc | 4.68 | $ 2.487 Millions | $ 0.531 Millions | | P3 Health Partners Inc | 4.35 | $ 725.919 Millions | $ 166.840 Millions | | Neuronetics Inc | 3.85 | $ 74.563 Millions | $ 19.386 Millions | | Apyx Medical Corporation | 3.39 | $ 50.647 Millions | $ 14.924 Millions | | Bioventus Inc | 3.39 | $ 641.238 Millions | $ 189.062 Millions | | Strata Skin Sciences Inc | 3.17 | $ 30.085 Millions | $ 9.496 Millions | | Tandem Diabetes Care Inc | 2.74 | $ 641.638 Millions | $ 233.875 Millions | | Zynex inc | 2.59 | $ 84.987 Millions | $ 32.816 Millions | | The Pennant Group Inc | 2.58 | $ 446.932 Millions | $ 172.993 Millions | | Ir med Inc | 2.45 | $ 0.891 Millions | $ 0.363 Millions | | Baxter International Inc | 2.42 | $ 18,669.000 Millions | $ 7,708.000 Millions | | Cytosorbents Corporation | 2.19 | $ 36.690 Millions | $ 16.737 Millions | | Stereotaxis Inc | 2.17 | $ 24.658 Millions | $ 11.356 Millions | | Novocure Limited | 2.13 | $ 771.413 Millions | $ 361.750 Millions | | Patterson Companies Inc | 1.92 | $ 1,828.508 Millions | $ 952.501 Millions | | Insulet Corporation | 1.89 | $ 1,883.200 Millions | $ 998.400 Millions | | Dexcom Inc | 1.75 | $ 4,251.800 Millions | $ 2,434.300 Millions | | Artivion Inc | 1.68 | $ 494.483 Millions | $ 295.056 Millions | | Haemonetics Corporation | 1.63 | $ 1,478.553 Millions | $ 905.368 Millions | | Predictive Oncology Inc | 1.59 | $ 6.493 Millions | $ 4.094 Millions | | Conmed Corporation | 1.52 | $ 1,338.840 Millions | $ 881.832 Millions | | Vivos Therapeutics Inc | 1.50 | $ 9.495 Millions | $ 6.347 Millions | | Adm Tronics Unlimited Inc | 1.46 | $ 1.487 Millions | $ 1.020 Millions | | Integra Lifesciences Holdings Corp | 1.42 | $ 2,181.996 Millions | $ 1,534.195 Millions | | Nuo Therapeutics Inc | 1.37 | $ 0.822 Millions | $ 0.599 Millions | | Henry Schein Inc | 1.36 | $ 5,652.000 Millions | $ 4,148.000 Millions | | Therapeutic Solutions International Inc | 1.34 | $ 2.461 Millions | $ 1.836 Millions |
|
